Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates

Xu, Shi
November 2015
Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3577
Academic Journal
Purpose: This review discusses the molecular mechanism involved in the targeting and delivery of antibody-drug conjugates (ADCs), the new class of biopharmaceuticals mainly designed for targeted cancer therapy. Methods: this review goes over major progress in preclinical and clinical studies of ADCs, in the past 5 years. Results: The pharmacokinetics and pharmacodynamics of ADCs involve multiple mechanisms, including internalization of ADCs by target cells, intracellular trafficking, release of conjugated drugs, and payload. Conclusion: These mechanisms actually jointly determine the efficacy of ADCs. Therefore, the optimization of ADCs should take them as necessary rationales.


Related Articles

  • Monoclonal Antibodies and Biosimilars – A Selection of Analytical Tools for Characterization and Comparability Assessment. Sandra, Koen; Vandenheede, Isabel; Dumont, Emmie; Sandra, Pat // LC-GC Europe;Oct2015 Supplement Advances in Biopharmaceutical Analysis, p16 

    Monoclonal antibodies (mAbs) have emerged as important therapeutics for the treatment of life-threatening diseases including cancer and autoimmune diseases. With the top-selling mAbs evolving out of patent there has been a growing interest in the development of biosimilars. In demonstrating...

  • Research & Markets: Competitor Analysis: Antibody-Drug Conjugates (ADC).  // Biomedical Market Newsletter;12/14/2011, Vol. 21, p1 

    The article focuses on the "Competitor Analysis: Antibody-Drug Conjugates (ADC)" report released from Research & Markets Ltd. The report provides information on the current projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology including drug...

  • A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design. Vasalou, Christina; Helmlinger, Gabriel; Gomes, Bruce // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Antibody drug conjugates (ADCs) represent novel anti-cancer modalities engineered to specifically target and kill tumor cells expressing corresponding antigens. Due to their large size and their complex kinetics, these therapeutic agents often face heterogeneous distributions in tumors, leading...

  • Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Doronina, Svetlana O; Toki, Brian E; Torgov, Michael Y; Mendelsohn, Brian A; Cerveny, Charles G; Chace, Dana F; DeBlanc, Ron L; Gearing, R Patrick; Bovee, Tim D; Siegall, Clay B; Francisco, Joseph A; Wahl, Alan F; Meyer, Damon L; Senter, Peter D // Nature Biotechnology;Jul2003, Vol. 21 Issue 7, p778 

    We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to...

  • Drug design: Increasing stability of ADCs. Crunkhorn, Sarah // Nature Reviews Drug Discovery;Nov2014, Vol. 13 Issue 11, p812 

    The article focuses on the importance of maleimide in improving the stability of antibody-drug conjugates (ADCs) for the treatment of cancer.

  • Lonza has conjugates project.  // ICIS Chemical Business;5/21/2007, Vol. 2 Issue 67, p36 

    The article reports on the antibody drug conjugates project of Lonza. The antibody drug conjugates consist of a highly active chemical substance coupled with a biotechnologically manufactured antibody. The conjugates can be used in targeted treatment of cancers. Lonza is operating a...

  • BIOPHARMA CMO Update. Downey, William // Contract Pharma;Jun2014, Vol. 16 Issue 5, p60 

    The article discusses the growth of the demand for biopharmaceutical contract manufacturing services. Topics include the increase in sales observed by contract manufacturing organization (CMO) leaders in 2013, the positive impact of the increased investment in biopharma on CMO, and the...

  • Wondering What You Missed in BioWorld Insight?  // BioWorld Today;8/8/2012, Vol. 23 Issue 153, p7 

    The article provides updates in the biopharmaceutical industry in the U.S. including the field of research surrounding antibody-drug conjugates (ADCs), Amarin Corp. PLC's triglyceride-lowering drug Vascepa, and a projected 1 .6 million new cancer cases and 577,190 deaths from cancer.

  • Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy. Krauss, J�rgen; Arndt, Michaela A. E.; D�bel, Stefan; Rybak, Susanna M. // Current Pharmaceutical Biotechnology;Jun2008, Vol. 9 Issue 3, p231 

    Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase), the first ribonuclease being evaluated as a therapeutic in humans, has...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics